A study in people with obesity to test the effects of different doses of BI 456906 compared with semaglutide on glucagon receptor activity in the liver
Phase 1
Recruiting
- Conditions
- No targeted indication. Male and female subjects with obesity.
- Registration Number
- 2024-515417-17-00
- Lead Sponsor
- Boehringer Ingelheim International GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing, recruiting
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Academisch Medisch Centrum
🇳🇱Amsterdam, Netherlands
Academisch Medisch Centrum🇳🇱Amsterdam, NetherlandsVictor GerdesSite contact31205129333v.e.gerdes@amsterdamumc.nl